Opioid Crisis Legal Battle: Insurers and Pharmacies Face Off
A significant legal and financial matter is developing between pharmacies and insurance firms concerning the economic impacts of the opioid crisis on states and healthcare providers. An appellate court panel from the 11th Circuit has opted not to determine if insurers must defend pharmacies involved in numerous opioid-related lawsuits. Instead, the matter has been referred to the Supreme Courts of Georgia and Florida for clarification.
This issue could have profound effects on the insurance markets in these states, given the substantial financial implications for numerous stakeholders. The panel, consisting of Judges Nancy Abudu, Robin Rosenbaum, and Britt Grant, each appointed by different administrations, highlighted the potential market impact in their opinions.
The central legal question focuses on whether insurance policies must cover claims for financial losses tied to the opioid epidemic, despite not being classified as damages for "bodily injury" under current policy language. While insurers acknowledge that opioid addiction and overdose are "bodily injuries," they contend the claims against pharmacies do not constitute damages directly "because of" these injuries.
Florida lacks a definitive interpretation of the causation required by these policies, leading to ambiguities that necessitate further judicial review. The panel clarified that such determinations fall under state law, not federal courts. For instance, Georgia courts have previously ruled that ambiguous insurance terms should generally provide coverage.
Two insurers, Allied Property & Casualty Insurance Company and AMCO Insurance Company, seek a declaratory judgment asserting they have neither the duty to defend nor indemnify under Georgia laws. Bloodworth Wholesale Drugs, implicated in 26 lawsuits since 2017, and Publix, facing over 60 lawsuits, are pursuing legal actions against these insurers to contest denial of coverage.
These lawsuits allege that pharmacies failed to properly control or scrutinize opioid orders, resulting in widespread health impacts that state and local governments, hospitals, and healthcare entities must financially address. The Centers for Disease Control and Prevention highlight a sharp increase in deaths involving opioids from 1999 to 2023, though some recent declines have been observed.
The ongoing legal deliberations in Georgia and Florida's highest courts are closely monitored, given their potential to set significant precedents affecting insurers and policyholders within the healthcare industry.